secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001104659-23-062930
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics effects 1-for-20 reverse stock split to meet Nasdaq bid price rule
--------------------------------------------------------------------------------

- 1-for-20 reverse split effective 4:05 pm ET May 22, 2023; trading on split-adjusted basis begins May 23.
- Pre-split outstanding shares ~16,998,534 reduced to ~849,926 post-split shares.
- Reverse split intended to satisfy Nasdaq minimum $1.00 bid price continued listing requirement.
- No fractional shares issued; cash paid for fractional interests based on May 22 closing price.
- Trading symbol RNAZ unchanged; new CUSIP 89357L 204; Vstock Transfer LLC acting as exchange agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923062930/0001104659-23-062930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923062930/tm2316322d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-062930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer